Table 1 Clinical data of included studies
From: Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis
Treatment & study | Location (language) | Age (years) | Sex | Placebo | Itopride | Mosapride | Domperidone | Acotiamide | Metoclopramide | Trimebutine | Dosage & treatment duration |
|---|---|---|---|---|---|---|---|---|---|---|---|
Effective/Total | Effective/Total | Effective/Total | Effective/Total | Effective/Total | Effective/Total | Effective/Total | |||||
Van Ganse W (1978) | Belgium (English) | mean 50 (range 24–82) | M: 42 F: 31 (2 drop out) | 9/36 |  |  | 31/35 |  |  |  | 10 mg × 4/day, 2 weeks |
Bekhti A (1979) | Belgium (English) | domperidone: median 43.5 (range 19–67), placebo: 47 (50–73) |  | 4/20 |  |  | 13/20 |  |  |  | 10 mg × 4/day, 4 weeks |
De Loose F (1979) | Belgium (English) | median 40 (range 19–63) | M: 16, F: 27 (multiphase study) | 22/70 |  |  | 62/68 |  |  |  | 10 mg × 4/day, 2 weeks |
De Loose (1979) | Belgium (English) | median 40 (range 19–63) | M: 16, F: 27 (multiphase study) | 22/70 |  |  |  |  | 50/68 |  | 10 mg × 4/day, 2 weeks |
Van Outryve M (1979) | Belgium (English) | domperidone: median 63 (range 32–80), placebo: 52 (25–81) | M: 16, F: 22 | 11/22 |  |  | 13/16 |  |  |  | 20 mg, × 3/day, 2 weeks |
Van de Mierop L (1979) | Belgium (English) | median 56 (range 32–76) | M: 9, F: 23 | 2/15 |  |  | 12/17 |  |  |  | 10 mg, × 3/day, 4 weeks |
Davis RH (1988) | US (English) | mean 30 (range 18–48) | M: 1, F: 15 | 3/7 |  |  | 7/9 |  |  |  | 20 mg, × 2/day, 6 weeks |
Teixeira CR (2000) | Portugal (Portuguese) | 39 ± 13, (mean ± SD), (range 18–74) | M: 19, F: 46 (22 cisapride allocated population) | 5/16 |  |  |  |  |  | 18/27 | 200 mg, × 3/day, 15 days |
Zhou LY (2000) | China (Chinese) | itopride: 42.6 ± 12.3, domperidone: 42.6 ± 12.8, (mean ± SD) | Itopride; M: 34. F: 66, Domperidone; M: 38, F: 63 |  | 79/100 |  | 74/101 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks |
Hallerbäck BI (2002) | Europe (multicenter) (English) | range 18–75 | Mosapride; M: 49, F: 94, Placebo; M: 44, F: 97 | 84/141 |  | 84/143 |  |  |  |  | 10 mg × 2/day, 6 weeks |
Sun Jing (2003) | China (Chinese) | range 18–70 |  |  | 58/115 |  | 62/117 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks |
Mo Jian-zhong (2003) | China (Chinese) | mean 47.39 (range 21–70) | M: 29, F: 51 |  | 38/39 |  | 29/40 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 2 weeks |
Chen Xi (2004) | China (Chinese) | itopride: 34.7 ± 8.9, domperidone: 36.3 ± 11.1, (mean ± SD) |  |  | 17/20 |  | 14/20 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks |
Amaranpukar DN (2004) | India (English) | itopride: 45.23 ± 13.07, mosapride: 39.79 ± 10.82, (mean ± SD) | M: 30, F: 30 |  | 28/30 | 19/30 |  |  |  |  | itopride 50 mg, mosapride 5 mg × 3/day, 2 weeks |
Chen Shi-yao (2004) | China (Chinese) | mosapride: 44 ± 12, domperidone: 43 ± 13, (mean ± SD), | M: 108, F: 123 |  |  | 106/118 | 92/113 |  |  |  | mosapride 5 mg, domperidone 10 mg × 3/day, 4 weeks |
Zhu Chang-Qing (2005) | China (Chinese) |  |  |  | 77/119 |  | 73/117 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks |
Li Yan-Hong (2005) | China (Chinese) | itopride: 38 ± 12, domperidone: 38 ± 12, (mean ± SD) | M: 94, F: 106 |  | 89/100 |  | 89/100 |  |  |  | itopride 50 mg, domperidone 10 mg × 3/day, 4 weeks |
Matsueda K (2005) | Japan (English) | mean 39 | 60% female | 21/32 |  |  |  | 28/33 |  |  | 100 mg × 3/day, 4 weeks |
Holtmann G (2006) | Germany (English) | 47.9 ± 15.8, (mean ± SD) | 63.5% female | 56/136 | 75/128 |  |  |  |  |  | 100 mg × 3/day, 8 weeks |
Talley NJ (2008) | US (English) |  |  | 35/104 |  |  |  | 58/103 |  |  | 200 mg × 3/day, 12 weeks |
Talley NJ (2008) | US (English) | itopride: 42.6 ± 12.8, placebo: 43.0 ± 12.5, (mean ± SD) | Itopride: female 64.6%, placebo: female 69.8% | 112/316 | 115/304 |  |  |  |  |  | 100 mg × 3/day, 8 weeks |
Lin Jinkun (2009) | China (Chinese) | range 19–65 | M: 20, F: 40 | 12/30 |  | 25/30 |  |  |  |  | 5 mg × 3/day, 2 weeks |
Yeon-Mi Kim (2010) | Korea (Korean) | mosapride: 29.79 ± 7.56, placebo: 31.86 ± 11.53, (mean ± SD) | M: 4, F: 24 | 5/14 |  | 10/14 |  |  |  |  | 5 mg × 3/day, 2 weeks |
Matsueda K (2010) | Japan (English) | acotiamide: 37.5 ± 11.5, placebo: 37.3 ± 10.2, (mean ± SD) | M: 100, F: 111 | 43/107 |  |  |  | 52/104 |  |  | 100 mg × 3/day, 4 weeks |
Kusunoki H (2012) | Japan (English) | acotiamide: 40.3 ± 13.2, placebo: 40.6 ± 13.0, (mean ± SD) | M: 13, F: 24 (5 drop out) | 3/21 |  |  |  | 6/21 |  |  | 100 mg × 3/day, 14–18 days |
Matsueda K (2012) | Japan (English) | acotiamide: 37.6 ± 10.7, placebo: 37.1 ± 9.9, (mean ± SD) | M: 363, F: 529 (5 drop out) | 154/445 |  |  |  | 235/452 |  |  | 100 mg × 3/day, 4 weeks |
Total | Â | Â | Â | 603/1602 | 576/955 | 244/335 | 571/773 | 379/713 | 50/68 | 18/27 | Â |